PMID- 31496820
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231013
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 11
DP  - 2019
TI  - Impact of tivozanib on patient outcomes in treatment of advanced renal cell 
      carcinoma.
PG  - 7779-7785
LID - 10.2147/CMAR.S206105 [doi]
AB  - Renal cell carcinoma (RCC) is the most common type of kidney malignancy, and the 
      clear-cell subtype represents the majority of RCCs. RCC is a heterogeneous 
      disease in terms of genetic and histological features which determine the 
      behavior of the disease. The von Hippel-Lindau (VHL) is a tumor suppressor gene 
      and mutations of this gene are seen in 95% of clear-cell RCCs. Inactivation 
      of VHL causes the accumulation of hypoxia-inducible factor-1 (HIF-1), and in 
      turn, accumulation of HIF-1 induces overexpression of vascular endothelial growth 
      factor (VEGF); the increase in VEGF expression makes RCC a highly vascularized 
      tumor, and forms the rationale for antiVEGF treatment. In the past decade, 
      improvement in the survival of RCC patients has been observed due to new 
      effective therapies, such as antiVEGF and mammalian target of rapamycin (mTOR) 
      targeting agents and immune checkpoint inhibitors. The majority of VEGF targeted 
      agents are not just selective to VEGF receptors, but usually also have inhibitory 
      effects on other kinases, such as c-KIT and FLT3. Tivozanib is an extremely 
      potent and selective tyrosine kinase inhibitor (TKI) of VEGFR-1, 2, and 3, with a 
      relatively long half-life, that is approved by the European Commission for the 
      treatment of advanced/metastatic RCC. Tivozanib, at very low serum concentration 
      can inhibit phosphorylation of VEGFR -1, -2, and -3 tyrosine kinase activity. 
      This article summarizes the clinical data on tivozanib in the treatment of 
      advanced/metastatic RCC.
FAU - Yalcin, Suayib
AU  - Yalcin S
AD  - Hacettepe University Institute of Cancer, Department of Medical Oncology, Ankara, 
      Turkey.
FAU - Lacin, Sahin
AU  - Lacin S
AD  - University of Health Sciences, Diyarbakir Gazi Yasargil Training and Research 
      Hospital, Department of Medical Oncology, Diyarbakir, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20190816
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC6701608
OTO - NOTNLM
OT  - clear-cell carcinoma
OT  - renal cell carcinoma
OT  - tivozanib
OT  - tyrosine kinase inhibitors
OT  - vascular endothelial growth factor
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/09/10 06:00
MHDA- 2019/09/10 06:01
PMCR- 2019/08/16
CRDT- 2019/09/10 06:00
PHST- 2019/02/20 00:00 [received]
PHST- 2019/06/13 00:00 [accepted]
PHST- 2019/09/10 06:00 [entrez]
PHST- 2019/09/10 06:00 [pubmed]
PHST- 2019/09/10 06:01 [medline]
PHST- 2019/08/16 00:00 [pmc-release]
AID - 206105 [pii]
AID - 10.2147/CMAR.S206105 [doi]
PST - epublish
SO  - Cancer Manag Res. 2019 Aug 16;11:7779-7785. doi: 10.2147/CMAR.S206105. 
      eCollection 2019.